Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Polska Grupa Hutnicza's Net Margin % or its related term are showing as below:
WAR:PGH'
s Net Margin % Range Over the Past 10 Years
Min: -5715.56 Med: -290.62 Max: 14.49
Current: -630.46
WAR:PGH's Net Margin % is ranked worse than 95.63% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.48
vs WAR:PGH: -630.46
Polska Grupa Hutnicza (WAR:PGH) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Polska Grupa Hutnicza Net Margin % Related Terms
Polska Grupa Hutnicza Net Margin % Historical Data
* Premium members only.
The historical data trend for Polska Grupa Hutnicza's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:PGH vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Polska Grupa Hutnicza's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polska Grupa Hutnicza Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Polska Grupa Hutnicza's Net Margin % distribution charts can be found below:
* The bar in red indicates where Polska Grupa Hutnicza's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polska Grupa Hutnicza (WAR:PGH) has a Net Margin % of -622.86% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Polska Grupa Hutnicza and its competitors. According to the industry distribution chart, Polska Grupa Hutnicza ranks #919 out of 961 companies in the Drug Manufacturers industry, placing it in the top 95.6%.
Is Polska Grupa Hutnicza's Net Margin % too high?
Polska Grupa Hutnicza's current Net Margin % is -622.86%. Based on the distribution chart, Polska Grupa Hutnicza ranks #919 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Polska Grupa Hutnicza has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Polska Grupa Hutnicza's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Polska Grupa Hutnicza ranks #919 out of 961 companies for Net Margin %. This places Polska Grupa Hutnicza in the lower half of its industry. The industry median Net Margin % is 5.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.48, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Polska Grupa Hutnicza and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polska Grupa Hutnicza's current Net Margin % is -622.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polska Grupa Hutnicza stock overvalued right now?
Based on GuruFocus' analysis, Polska Grupa Hutnicza (WAR:PGH) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.31, compared to a current price of zł3.97 — trading 1180.6% above its estimated fair value. The current Net Margin % is -622.86%. Polska Grupa Hutnicza's overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Polska Grupa Hutnicza (WAR:PGH), the current Net Margin % is -622.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polska Grupa Hutnicza (WAR:PGH) Overvalued in 2026?
Based on GuruFocus' analysis, Polska Grupa Hutnicza stock appears to be overvalued.
The current stock price of zł3.97 is trading 1180.6% above its estimated GF Value™ of zł0.31.
GuruFocus considers Polska Grupa Hutnicza to be Significantly Overvalued.
Key valuation signals for WAR:PGH:
Net Margin %: -622.86%
GF Value™: zł0.31 vs. price of zł3.97 (1180.6% above fair value)
No single metric tells the full story. See the WAR:PGH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hemp & Health SA is engaged in hemp and cannabis cultivation. The company processes harvested crops such as CBD and CBG, used for the production of white labels and private labels oils, creams, dried herbs and liquids for vaporization.
31GF Score
Get the complete analysis for WAR:PGH
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:PGH has been successfully added to your 
